Arcoma Management

Management criteria checks 1/4

Arcoma's CEO is Mattias Leire, appointed in Feb 2023, has a tenure of 1.83 years. directly owns 1.12% of the company’s shares, worth SEK1.59M. The average tenure of the management team and the board of directors is 1.8 years and 7.9 years respectively.

Key information

Mattias Leire

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure1.8yrs
CEO ownership1.1%
Management average tenure1.8yrs
Board average tenure7.9yrs

Recent management updates

Have Insiders Sold Arcoma AB (STO:ARCOMA) Shares Recently?

Jan 14
Have Insiders Sold Arcoma AB (STO:ARCOMA) Shares Recently?

Recent updates

Lacklustre Performance Is Driving Arcoma AB's (STO:ARCOMA) 28% Price Drop

Nov 09
Lacklustre Performance Is Driving Arcoma AB's (STO:ARCOMA) 28% Price Drop

Solid Earnings Reflect Arcoma's (STO:ARCOMA) Strength As A Business

Aug 22
Solid Earnings Reflect Arcoma's (STO:ARCOMA) Strength As A Business

At kr15.20, Is Arcoma AB (STO:ARCOMA) Worth Looking At Closely?

Aug 07
At kr15.20, Is Arcoma AB (STO:ARCOMA) Worth Looking At Closely?

Is Now The Time To Look At Buying Arcoma AB (STO:ARCOMA)?

Apr 26
Is Now The Time To Look At Buying Arcoma AB (STO:ARCOMA)?

Arcoma AB's (STO:ARCOMA) P/E Is Still On The Mark Following 25% Share Price Bounce

Feb 06
Arcoma AB's (STO:ARCOMA) P/E Is Still On The Mark Following 25% Share Price Bounce

Is Arcoma (STO:ARCOMA) A Risky Investment?

Jan 15
Is Arcoma (STO:ARCOMA) A Risky Investment?

We Think Arcoma (STO:ARCOMA) Is Taking Some Risk With Its Debt

Sep 11
We Think Arcoma (STO:ARCOMA) Is Taking Some Risk With Its Debt

Is Arcoma (STO:ARCOMA) Using Too Much Debt?

Jun 08
Is Arcoma (STO:ARCOMA) Using Too Much Debt?

Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?

Apr 27
Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?

Does Arcoma (STO:ARCOMA) Have A Healthy Balance Sheet?

Dec 22
Does Arcoma (STO:ARCOMA) Have A Healthy Balance Sheet?

Is Arcoma (STO:ARCOMA) Using Too Much Debt?

May 03
Is Arcoma (STO:ARCOMA) Using Too Much Debt?

These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Extensively

Oct 28
These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Extensively

Is Arcoma (STO:ARCOMA) A Risky Investment?

Mar 17
Is Arcoma (STO:ARCOMA) A Risky Investment?

Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?

Feb 04
Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?

Have Insiders Sold Arcoma AB (STO:ARCOMA) Shares Recently?

Jan 14
Have Insiders Sold Arcoma AB (STO:ARCOMA) Shares Recently?

Arcoma AB's (STO:ARCOMA) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Jan 12
Arcoma AB's (STO:ARCOMA) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Reasonably Well

Dec 17
These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Reasonably Well

Estimating The Fair Value Of Arcoma AB (STO:ARCOMA)

Nov 21
Estimating The Fair Value Of Arcoma AB (STO:ARCOMA)

CEO

Mattias Leire (43 yo)

1.8yrs

Tenure

Mr. Mattias Leire is Chief Executive Officer of Arcoma AB from February 2023. He joined the Arcoma AB in 2023. He has extensive experience from leading positions, including many years within Atos Medical....


Leadership Team

NamePositionTenureCompensationOwnership
Mattias Leire
Chief Executive Officer1.8yrsno data1.12%
SEK 1.6m
Johan Dahlberg
Chief Financial Officer2.6yrsno data0.045%
SEK 64.5k
Daniel Warawasowski
Global Sales Directorless than a yearno datano data

1.8yrs

Average Tenure

41yo

Average Age

Experienced Management: ARCOMA's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Jan Wahlstrom
Independent Director2.6yrsSEK 100.00k0.53%
SEK 752.5k
Mats Thoren
Director14.9yrsSEK 100.00k5.07%
SEK 7.2m
Lars Kvarnhem
Chairman7.9yrsSEK 400.00kno data

7.9yrs

Average Tenure

53yo

Average Age

Experienced Board: ARCOMA's board of directors are considered experienced (7.9 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 14:54
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Arcoma AB is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hjalmar JernstromPenser Access